Cancer | Novartis

Press Release
Nov 19, 2025

Novartis announces plans to build flagship manufacturing hub in North Carolina
Story
May 31, 2024

A legacy of blood cancer innovation
Press Release
Apr 23, 2024

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Story
Apr 08, 2024

Drug delivery, service delivery, and the future of cancer care
Story
Feb 14, 2024

Listening to the CML patient community
Press Release
Feb 05, 2024

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Story
Jan 31, 2024

Facing the fear of breast cancer recurrence
Press Release
Jan 19, 2024

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
Press Release
Oct 23, 2023

Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
Press Release
Oct 20, 2023

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Press Release
Oct 05, 2023

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Press Release
Sep 25, 2023

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)